Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP001372

Drug Information
SynonymsNCGC00024072-03; 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl-; Ebselenum [Latin]; NCGC00178610-01; E 3520; SPBio_001301; MLS001148646; Ebseleno; KBio2_002630; C13H9NOSe; Prestwick3_000740; NCGC00015412-13; CAS-60940-34-3; KBio2_005198; HMS502P13; NINDS_000951; HMS1570C22; NCGC00015412-03; PZ51; BCBcMAP01_000149; PZ 51; NCGC00024072-04; CID3194; ebselen; AC-1124; 2-Phenyl-1,2-benzisoselenazolin-3-one; Spectrum4_000445; RP 60931; CPD000058445; EU-0100541; AC1L1FDW; UNII-40X2P7DPGH; Prestwick0_000740; NCGC00015412-01; Bio2_000542; CHEBI:175507; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; KBioGR_000062; HMS2052N09; Spectrum3_000799; Lopac0_000541; HMS1989D04; Ebselene; SAM001247071; BSPBio_001342; Harmokisane; BSPBio_002538; Spectrum5_001713; AB00053217; QTL1_000035; HMS1361D04; nchembio.109-comp1; BPBio1_000770; Ebseleno [Spanish]; IDI1_000951; DivK1c_000951; BRD-K29359156-001-06-1; Prestwick2_000740; SMR000058445; Prestwick_1057; DR 3305; I09-1611; Prestwick1_000740; BSPBio_000700; Ebselen [INN]; PZ-51; CHEMBL51085; NSC 639762; CCRIS 3714; Ebselenum; NCGC00015412-06; HMS1791D04; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; SPI-3005; LS-33527; MLS000028488; KBio3_000124; Bio2_000062; NCGC00024072-05; MLS-0003066.0001; Ebselene [French]; Spectrum2_001441; NCGC00178610-03; 60940-34-3; KBio2_000062; SPI-1005; KBioGR_000830; KBio3_000123; E3520_SIGMA; SPBio_002639; NSC639762; DR-3305; NCGC00178610-02; C042986; KBio3_001758; NCGC00015412-02; KBio1_000951; KBioSS_000062; Lopac-E-3520; IDI1_033812; 2-phenyl-1,2-benzoselenazol-3-one
IndicationReperfusion injury and stroke
[ICD9: 410, 434.91   ICD10: I21, I22, I61-I63]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2    
Therapeutic ClassFibrinolytic Agents
CAS NumberCAS 60940-34-3
PubChem Compound IDCID 3194.
PubChem Substance IDSID 183892.
TargetSerum albuminBinder[2]
Ref 1Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112. To Reference
Ref 2Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543